Runnymede Capital Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Runnymede Capital Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5	Closed	–	–	293
2025 Q1	$0	Hold	5	–	–	﹤0.01%	314
2024 Q4	$0	Buy	+5	New	–	﹤0.01%	285

Runnymede Capital Advisors's NAVB Position: Q2 2025 in Review

Runnymede Capital Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2025, closing a stake of 5 shares.

Runnymede Capital Advisors first reported a position in NAVB in Q4 2024 and held it in 2 quarters. The position peaked at $0 in Q1 2025. 1 fund tracked by Wall St. Rank holds NAVB as of Q2 2025.

Runnymede Capital Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2025 after selling out during the quarter.
Runnymede Capital Advisors sold 5 Navidea Biopharmaceuticals Inc. shares in Q2 2025.
Runnymede Capital Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2024 and held it in 2 quarters.
Runnymede Capital Advisors's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q1 2025.
1 fund tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2025.

Based on Runnymede Capital Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.